Two-drug attack targets hard-to-treat cancers
NCT ID NCT04042701
First seen Nov 18, 2025 · Last updated Apr 29, 2026 · Updated 15 times
Summary
This early-phase study tests a combination of two drugs—trastuzumab deruxtecan and pembrolizumab—in people with advanced breast or non-small cell lung cancer that has spread. The goal is to find the safest dose and see if the combo shrinks tumors. About 115 adults with HER2-positive cancers will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Poitiers
Poitiers, 86000, France
-
CHUTimone
Marseille, 13385, France
-
Cancer Specialists of North Florida (Cbo)
Jacksonville, Florida, 32256, United States
-
Center for Cancer & Blood Disorders
Bethesda, Maryland, 20817, United States
-
Centre Hospitalier Intercommunal de Créteil
Créteil, 94000, France
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Hope Cancer Center of East Texas
Tyler, Texas, 75701, United States
-
Hopital Universitario Insular de Gran Canaria
Las Palmas de Gran Canaria, 35016, Spain
-
Hospital General Univ. Gregorio Marañon
Madrid, 28009, Spain
-
Hospital Teresa Herrera (C.H.U.A.C)
A Coruña, 15006, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Miguel Servet
Zaragoza, 50009, Spain
-
Hospital Universitario Virgen Macarena
Seville, 41009, Spain
-
Hospital de la Santa Creu i de Sant Pau
Barcelona, 08025, Spain
-
Inst. Oncologico Baselga Hospital Quiron
Barcelona, 08023, Spain
-
Institut Bergonie
Bordeaux, 33000, France
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Institut PAOLI-CALMETTES
Marsielle, 13273, France
-
MD Anderson Cancer Center
Madrid, 28033, Spain
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
Moffit Cancer Center
Tampa, Florida, 33612, United States
-
Moffitt Cancer Center
Tampa, Florida, 32256, United States
-
Royal Marsden Hosptial
Sutton, SM2 5PT, United Kingdom
-
Sarah Cannon Research Institute (SCRI)
London, W1G 6AD, United Kingdom
-
Siteman Cancer Center-Washington University
St Louis, Missouri, 63110, United States
-
The Christie NHS Fond. Trust
Manchester, M20 4BX, United Kingdom
-
The Royal Marsden NHS Foundation Trust
London, SW3 6JJ, United Kingdom
-
Univ. du Cancer de Toulouse
Toulouse, 31100, France
-
Univ. of Cali. San Francisco Medical Center
San Francisco, California, 94143, United States
-
Yale Cancer Center
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.